Interested in stem cell developments.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Like many other things Operation Warp Speed wasn't Trump's idea. Many others had to pressure him to do it but he is still happy to try to take full credit for it.
This refers to daily treatment with AM-301 started 24 or 30 hours post inoculation. I don't think many people getting infected will be starting treatment that quickly.
I think Zyesami will seize the day with radiographic and x-ray results of lungs. AM-301 is making no claims in that area. It appears they only look at nasal epithelium cell results.
Trump was too busy pushing hydroxychloroquine and drinking bleach.
As well, the hydroxychloroquine craziness.
A-M301 is primarily for allergic rhinitis and preliminary preclinical data only suggest therapeutic utility post SARS-CoV-2 infection.
SaNOtize initiates trials of nasal spray against Covid-19 in UK
11th January 2021
SaNOtize Nitric Oxide Nasal Spray (NONS) is designed to exterminate the SARS-CoV-2 virus in the upper airways and stop its incubation and spread to the lungs.
https://www.clinicaltrialsarena.com/news/sanotize-trials-nasal-spray/
That, of course, was before the 95% success rates for the rMNA vaccines came out. Those statements may have been overstated in ways still they were much higher than expected and that did raise expectations. I do agree with him that it makes people act in a more carefree manner which promotes surges. We now are also paying much more attention to variants that are a constant threat. In the long run, he may very well be right that we may need annual or more often boosters. His arguments might add weight to the idea of asking for a commitment or strongly urging those who get Zyesami treatment to also get a vaccination. Even Trump got the vaccine after having been treated for COVID.
He certainly is right about the need for a very long surveillance period to follow-up on possible problematic effects of the vaccines.
Most people who take the Zyesami treatment will not have been vaccinated. I assume that Big Pharma would be happy to have them committed to taking a vaccination after treatment.
Maybe, maybe not. That is a good point. But possibly it could be done because if they didn't like it they could refuse the Zyesami and choose some other treatment. You can legally make people drive on one side of the road, wear a seat belt, not shout "Fire" in a theater. With the Pfizer and Moderna vaccines people are pretty much being forced to get two shots and if the COVID continues to surge and reaches very dangerous levels it may become legal to force vaccinations in general.
I wouldn't mind hearing more opinions on this issue.
Those who get COVID are unlikely to have been vaccinated. Again, it would make good sense for the Zyesami powers that be to make patients receiving Zyesami commit to being vaccinated at an appropriate time period after successful treatment. That would take care of the Big Pharma concerns and should make things move ahead well for Zyesami use.
Role of Aviptadil in COVID-19 (Zyesami, RLF100)
https://lastfuturist.com/role-of-aviptadil-in-covid-19/?fbclid=IwAR16T-nDwDqzf2fKDcpIfxwaORSb-MIUfpKt1uQcxW4-EKTbZD-O5VA6rn0
Thanks Narbooty. Sounds light the right explanation to me.
In tonight’s 60 Minutes episode on DARPA inspired attempts to end pandemics forever one highlight was about a woman on dialysis who was in an ICU near death with organ failures and septic shock.
At 3:45 in this episode an interesting discussion begins about use of a dialysis filter:
+++++++++++++++++++++++++++++++++++++++++++++++
Dr. Matt Hepburn: This is a filter that you can put on a dialysis machine.
"Patient 16", a military spouse, was in the ICU, near death with organ failure and septic shock when she was entered into a Defense Department COVID-19 study. Her family allowed us to witness the experimental 4-day treatment.
Dr. Gaeta: She's liberated from veso-active medications and her septic shock resolved. We also see improvements in her markers of inflammation. Those are all positive prognostic signs.
Bill Whitaker: You pass someone's blood through this--
Dr. Matt Hepburn: You pass it through--
Bill Whitaker: --it takes the virus out
Dr. Matt Hepburn: Takes the virus out, and puts the blood back in.
Within days, Patient 16 made a full recovery. The FDA has authorized the filter for emergency use. So far, doctors have used it to treat nearly 300 critically ill patients.
+++++++++++++++++++++++++++++++++++++++++++++++
The term veso-active used above has to be a misspelling of vasoactive. I assume the dialysis filter is designed to be used for many illnesses though I am not sure. It is possible Zyesami VIP is being referred since it is vasoactive.
Vasoactive means affecting the diameter of blood vessels. I don’t know how many medications for COVID might also be said to be vasoactive. Can anyone here make some knowledgeable comments on this issue.
Here is the episode with the discussion beginning at 3:45:
Military programs aiming to end pandemics forever
Bill Whitaker reports on how efforts Pentagon programs has helped in the fight against COVID-19 and may help end pandemics forever.
https://www.cbsnews.com/news/last-pandemic-science-military-60-minutes-2021-04-11/
Dr. Javitt on AstraZeneca vaccine: ‘It’s always a question of weighing the risks’
https://finance.yahoo.com/video/doctor-astrazeneca-vaccine-always-weighing-154733275.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
This interview will be very helpful. They give Dr. Javitt's credentials and ask him about vaccines and FDA policies as well as about his COVID treatment. In effect, they are treating him to be an impressive leader in the COVID field, which they should (because he is), but it is still very good to see him getting more and more public credit for that.
At least the person would be alive all those years down the road. Further, you could make the same argument about Zyesami use. Maybe too much short term use of even a natural hormone has bad long term effects, such as overuse of HGH.
Also, no one knows how long the various vaccination's protection lasts. The flu virus gets updated every year with guessing about new variants leading to partial protection. If the same has to be done with COVID vaccinations that is better than having no protection. For one thing, you leave yourself more vulnerable to getting an asymptomatic virus and spreading it around.
If you are counting totally on Zyesami you sure as hell better make sure you can get it right away which may mean you should have on hand a variety of checking methods for infection. If you get Zyesami right away I do think it will do the job but if you don't, depending on the lag, you could get not only mildly ill (which I also think the Zyesami would take care of) but, as a result, you might get some mild or worse "long hauler" symptoms. That possibility with this vicious virus scares me more than any vaccination.
You should get a vaccination. If you are afraid of getting the virus take the Pfizer or Moderna which use rMNA technology and which cannot possibly give you the virus. You can read a lot more about that here: https://www.cdc.gov/vaccines/covid-19/hcp/mrna-vaccine-basics.html
I think, in fact, that one way to deal with Zyesami possibly giving support to those who want to avoid vaccinations, thus taking money from the Big Pharma Cos. is to announce that everyone being treated with Zyesami has to commit to getting a vaccination at an appropriate interval after treatment.
I took the Pfizer with no problems except minor soreness the day after both times so I am okay with this requirement and I think Big Pharma would like if too and that could help move things along for Zyesami.
Excellent post.
dmsrz8, my assumption is that most complainers about PR here are talking about a fairly strong and somewhat sophisticated PR program, maybe not quite what Pfizer does but not as simple and probably as ineffective as what you are pushing for.
Pfizer aims to improve reputation, public relations with new ad campaign April 8, 2021
...... Pfizer — according to the website statistica.com, spent $3.1 billion advertising its products last year compared with a record $3.8 billion five years earlier. .....
I totally agree with this, Ria2. They currently don't have the resources to put great effort or funding into a big PR program. They know their main effort right now needs to be dealing with the FDA. If they succeed with the FDA they know they will get a lot of attention and will start bringing in money that will allow them to develop a PR program if they decide it is necessary or will be helpful.
I just received an email from Partners In Health (PIH) a great healthcare organization, to which I contribute, focusing on the most needy areas of the world.
It said:
++++++++++++++++++++++++++++
Needed: Oxygen
There isn’t enough medical oxygen in the world right now, but with your help, we can close the oxygen gap.
Medical oxygen is an essential component of treatment for the 19% of COVID-19 patients who develop severe or critical disease. It literally saves lives. But even before COVID-19, many of the communities we support around the world didn’t have enough oxygen to treat everyday illnesses that restrict breathing. As the COVID-19 pandemic exploded, so did demand for this already scarce, essential medical tool.
As emergency operations began, PIH teams knew that simply sending oxygen wouldn’t be a real solution. So we worked with local ministries of health to send something far better: the ability to make medical oxygen locally.
Initially, the rapid onset of this pandemic meant sending hundreds of backpack-sized oxygen concentrators, which isolate the lifesaving gas to help individual patients breathe and survive.
But there’s more. ??Now, we’re also sending entire oxygen plants. This vital infrastructure fits into standard shipping containers and can fill hundreds of portable cylinders per week to address the chronic underlying injustice of the oxygen gap, for communities and entire countries.
++++++++++++++++++++++++++++
I responded with an email pointing out that we now also have an additional very important and less expensive approach to the oxygen problem with Zyesami (RLF100, Aviptadil) which can be extremely helpful. I included links to the Javitt recent interview and the recent study results. I addressed it to Paul Farmer the founder and to development @ PIH. I hope it gets through to Farmer who is a brilliant guy and could easily respond by seriously checking this out right way.
I urge anyone else involved with PIH, or anyone interested, to voice your understanding of Zyesami and the role it could play to help with this serious problem they are trying to overcome.
Emails are:
paul_farmer@hms.harvard.edu, development@pih.org, info@pih.org,
I have said nothing about effective buy backs. I am holding what I have already bought. If you are speaking about Javitt I can't disagree with you more. I have seen many indications that right now, aside from family perhaps, Zyesami is his primary focus and just about the most important thing going on for him.
Now green and at a new high for the day. Where will it stop? Nobody knows.
Even as multiple steps are clearly being taken and coming together to launch Zyesami and bring out it's full potential in many areas, the trading pattern suggests the powers that be want to make it easy enough for impatient and ignorant holders to sell out and move away.
Quote by Dr. Javitt:
I will add to my previous comment that I have a feeling, nothing definitive, but a strong feeling that Javitt is pretty sure that when the full data analysis comes in the results will be evenbetter and will make a very powerful data based argument for Zysami.
I agree. There is no indication that Javitt would be brazenly fraudulent, quite the contrary.
Just for the record, my post, to which Allheartrader was responding, was dated April 4, 2021:
Relief Therapeutics Could Save our Lungs in the Third Wave
https://lastfuturist.com/relief-therapeutics-could-save-our-lungs-in-the-third-wave/
Relief Therapeutics Could Save our Lungs in the Third Wave
https://lastfuturist.com/relief-therapeutics-could-save-our-lungs-in-the-third-wave/
A brief summary of the White Board Doctor statements on the intravenous Aviptadil study and some other issues:
This is a very well designed (randomized, double blind, placebo, controlled) multi center study, “a high quality setup, the epitome of trial design.”
It is done with tremendously sick patients who have severe or critical COVID19 and respiratory failure.
The report is a news release and we don’t have the specific data and definitions, especially of recovery.
Still, all P values given were well under 0.05. The P values for recovery from respiratory failure (28 days 0.014 and 60 days 0.013) and overall survival with adjustments for site and vent status (<0.001).
HFNC recovery P values were also very impressive (28 days 0.017, 60 days 0.036 and at tertiary centers [large hospitals with multiple sub-specialists (0.007)]. Javitt had previously said “hospitalization data further suggest that patients treated at an earlier stage of illness (i.e., those who can be managed with HFNC) may have a better response to treatment.” That explains at least part of the purpose for this focus.
Javitt also said: “In reviewing our results you will notice a striking difference in the likelihood of survival and recovery seen at tertiary care hospitals, compared to that seen in regional hospitals that participated in our study. In no way should this be interpreted to imply that the quality of care that is frequently achieved in regional hospitals seen across the US, is in any way inferior to those seen in tertiary care medical centers. However, our study entered the regional hospitals just as the December and January surge hit, with 200% ICU over capacity, bays in the parking lot, and staffing shortages that were exacerbated by staff members contracting covid. There is ample evidence to show that as ICU capacity nears 100%, covid survival is reduced because of the enormous attention that must be paid to patients with covid19, from minute to minute in order to maximize survival and recovery.“
We do need the specific data and more precision about definition of some terms. Javitt also did say: “We have achieved all of the key endpoints we set out to achieve when we embarked on this study. We still have a great deal of work to do. We have not yet received or analyzed the thousands of laboratory values related to VIP levels, cytokines and other markers of covid pathology. We still have not analyzed the effect of ZyeSami of clearing of radiographic or x-ray findings in covid19, even though we have seen some very encouraging results in open label studies. There is much to learn from this study about critical covid19 and its treatment, and you can expect to hear more from us.”
Like clambottler, I can make some guesses. Though we don’t have the specific data the P values we have in this very well designed study are so good it is hard to imagine what would wipe them out as clambottler seems to think will happen. When everything is in it may make an even better story based on more specific data and evidence. I, myself, am especially looking forward to the “Improvement in chest radiographic and x-ray” results.
White Board Doctor provides a better explanation for what is happening at this point with the Zyesami study results, so far, than does clambottler:
ZYESAMI (Aviptadil, RLF-100) Quickens Recovery And Improves Survival In Critical COVID-19?
It is more important that Relief Mgmt and their partners, with limited resources, put most of their effort into working with the FDA and convincing them. Unless they succeed there nothing happens.
YEP!!!! It does look like n3n is another handle for clambottler.
Excellent post J-Belfort.
Good find go-wamu.
clambottler says:
I am going to will RLFTF up slowly.
Yes, like insulin (also a peptide), Aviptadil (Zyesami) is a small but mighty molecule. It has five separate mechanisms of action that set it apart from any other existing COVID therapy. These are:
It directly inhibits viral replication?
It has broad anti-inflammatory effects with decrease in II 6, cytokines and TNF?
It causes surfactant production?
It has direct bronchodilator effects to improve pulmonary blood-flow and increase the V/Q ratio (level of oxygenation)?
It inhibits apoptosis (cell death)?
In other words: "The die is cast."